A randomized, multicenter, phase II trial of camrelizumab (Cam) with and without metastasis-directed therapy (MDT) in recurrent/metastatic nasopharyngeal carcinoma (R/M-NPC).

被引：0
|
作者：
Zhang, Xin [1 ]
Yan, Jin [2 ]
Lei, Qianqian
Zhang, Lu
Yang, Jieying
Tan, Sze Huey
Chua, Melvin L. K.
Wang, Ying
Sui, Jiangdong
机构：
[1] Chongqing Univ, Coll Med, Chongqing, Peoples R China
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [41] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [42] Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Co-operative Oncology Group (HeCOG) study
    Mountzios, G.
    Dimopoulos, M. A.
    Bamias, A.
    Vourli, G.
    Kalofonos, H.
    Aravantinos, G.
    Fountzilas, G.
    Papadimitriou, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 450 - 450
  • [43] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).
    Delord, Jean-Pierre
    Hollebecque, Antoine
    De Boer, J. P.
    De Greve, Jacques
    Machiels, Jean-Pascal H.
    Leidner, Rom S.
    Ferris, Robert L.
    Rao, Shangbang
    Soumaoro, Ibrahima
    Cao, Z. Alexander
    Kang, Hyunseok
    Topalian, Suzanne Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Fetten, James Vincent
    Michel, Loren S.
    Kriplani, Anuja
    Morris, Luc
    Ostrovnaya, Irina
    Katabi, Nora
    Haque, Sofia
    Tran, Crystal
    Azar, Julian
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Phase II trial evaluating axitinib for patients with uaresectable, recurrent, or metastatic (R/M) bead and neck squamous cell carcinoma (HNSCC)
    Sacco, Assuntina Gesualda
    Zhao, Lill
    Carey, Thomas E.
    Dobrosotskaya, Irina Y.
    McHugh, Jonathan B.
    Chepeha, Douglas Brian
    Bradford, Carol Roasler
    Wolf, Gregory T.
    Prince, Mark E.
    Moyer, Jeffrey
    McKean, Erin Lynn
    McLean, Scott A.
    Malloy, Kelly M.
    Spector, Matthew E.
    Hogikyan, Norman D.
    Urba, Susan
    Ward, Brent
    Worden, Francis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
    Chan, A. T.
    Lee, V. H. F.
    Hong, R-L.
    Ahn, M-J.
    Chong, W. Q.
    Kim, S-B.
    Fuang, H. Gwo
    Caguioa, P. B.
    Ngamphaiboon, N.
    Ho, C.
    Aziz, M. A. S. Abdul
    Ng, Q. S.
    Yen, C-J.
    Soparattanapaisarn, N.
    Ngan, K. C. R.
    Kho, S. K.
    Swaby, R.
    Saraf, S.
    Ge, J.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S786 - S786
  • [48] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.
    Zhang, Li
    Yu, Gengsheng
    Jia, Jun
    Peng, Peijian
    Lin, Qing
    Xi, Xuping
    Peng, Jiewen
    Xu, Mingjun
    Chen, Dongping
    Lu, Xiaojun
    Wang, Rensheng
    Cao, Xiaolong
    Chen, Xiaozhong
    Lin, Zhixiong
    Xiong, Jian Ping
    Lin, Qin
    Xie, Conghua
    Li, Zhihua
    Zhao, Chong
    Hong, Shaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
    Tsao, Anne S.
    Hsieh, Ming-Hui
    Koczywas, Marianna
    Tu, Janet Chen
    Riess, Jonathan W.
    Tanvetyanon, Tawee
    Ma, Barbara Ting-Wen
    Zhao, Yingqi
    Redman, Mary Weber
    Edelman, Martin Joseph
    Gandara, David R.
    Kelly, Karen
    Gray, Jhanelle E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345